Debt-to-equity in % of Nurix Therapeutics, Inc. from Q2 2021 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nurix Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q2 2021 to Q3 2025.
  • Nurix Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Aug 2025 was 31.2 %, a 39.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Nurix Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 31.2 -20.4 -39.5% 31 Aug 2025
Q2 2025 30.4 -22.4 -42.4% 31 May 2025
Q1 2025 31.5 -22.3 -41.4% 28 Feb 2025
Q4 2024 39 -3.96 -9.21% 30 Nov 2024
Q3 2024 51.6 +16.7 +47.7% 31 Aug 2024
Q2 2024 52.8 +17.5 +49.5% 31 May 2024
Q1 2024 53.8 +15.6 +40.8% 29 Feb 2024
Q4 2023 43 +2.86 +7.13% 30 Nov 2023
Q3 2023 34.9 -5.68 -14% 31 Aug 2023
Q2 2023 35.3 -4.36 -11% 31 May 2023
Q1 2023 38.2 +2.76 +7.79% 28 Feb 2023
Q4 2022 40.1 +4.15 +11.5% 30 Nov 2022
Q3 2022 40.6 +5.35 +15.2% 31 Aug 2022
Q2 2022 39.7 +3.6 +9.98% 31 May 2022
Q1 2022 35.5 28 Feb 2022
Q4 2021 36 30 Nov 2021
Q3 2021 35.3 31 Aug 2021
Q2 2021 36.1 31 May 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.